RxDoctor Payments Data

Lauren Macaraeg, MD

Internal Medicine · Daly City, CANPI 1730612532

Payments from drug & device makers

$4,418in general payments, 2019–2025

Across 163 payments — averaging $27.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$585
  • Amgen$559
  • AstraZeneca$557
  • Boehringer Ingelheim$365
  • Calliditas Therapeutics US Inc.$363
  • Novartis$347
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,35499%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,418 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$322,258
Medicare patients
404
Services billed
2,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin47$65,976
FarxigaDapagliflozin Propanediol16$16,907
JanuviaSitagliptin Phosphate13$12,448
Sevelamer Carbonate20$6,763
ProsolParenteral Amino Acid 20% No.138$6,097
Bumetanide24$2,061
Valsartan21$1,257
Nifedipine ErNifedipine17$1,057
Torsemide20$1,033
Tamsulosin Hcl46$911
Finasteride56$900
Carvedilol52$772
Losartan Potassium79$628
Olmesartan Medoxomil15$570
Hydralazine Hcl29$547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$365$65,97647 claims
AstraZenecaFarxiga$557$16,90716 claims
ANI Pharmaceuticals, Inc.Valsartan$97$1,25721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Daly City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →